Imagion Biosystems Limited Overview
Imagion Biosystems is a clinical-stage medical imaging company seeking to introduce molecular specificity to magnetic resonance imaging (MRI) without radioactivity. Its MagSense® platform uses bio-safe superparamagnetic iron oxide nanoparticles conjugated to targeting moieties, such as antibodies, so that MRI contrast changes appear only where a target biomarker—initially HER2 on breast cancer cells—is present. The lead candidate, the MagSense® HER2 Imaging Agent, completed a first-in-human Phase 1 study in Australia in 2023 and received US FDA IND clearance in June 2026 for a three-part, multi-site Phase 1b/2 trial in HER2-positive breast cancer patients with suspected nodal involvement. Siemens Healthineers and Wayne State University support protocol optimisation. Prostate and ovarian agents sit in preclinical stage, contingent on funding. Commercially, Imagion is pre-revenue, has negative shareholders' equity, depends on frequent dilutive placements and a convertible note facility, and carries a going-concern material uncertainty. It is a binary, catalyst-driven micro-cap.
Company's own description
In its FY2025 Annual Report, the company describes its principal continuing activities as "Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance." The Executive Chairman's letter frames 2025 as the year Imagion "returned to its mission of developing the world's first molecular MRI imaging technology," re-established the development plan for the MagSense® HER2 imaging agent, and filed its first IND with the US FDA. Company boilerplate describes Imagion as a clinical-stage medical imaging company dedicated to transforming how cancer is diagnosed and treated, through MagSense®, a first-of-its-class MRI imaging agent intended to let clinicians detect cancer earlier and with greater precision.
How the technology works
MagSense® agents consist of iron oxide nanoparticle cores (historically described as approximately 25 nm with a specialised polymer coating) conjugated to custom targeting moieties such as antibodies. After intravenous injection, the particles accumulate at cells expressing the target biomarker. Under MRI, the presence of iron oxide produces a marked, identifiable change in image contrast. Management contrasts this with general-purpose gadolinium contrast agents, which distribute broadly and highlight vascularity rather than molecular identity. The company positions the approach as non-radioactive, in contrast to PET/SPECT molecular imaging.
The lead clinical use case is staging of HER2-positive breast cancer: determining whether cancer has spread to axillary lymph nodes, which drives surgical and systemic-therapy decisions. Current practice relies on ultrasound, biopsy and surgical sentinel lymph node biopsy. Imagion argues that a molecular MRI read could reduce invasive procedures and could potentially image response following neoadjuvant (pre-surgical) therapy.
Evolution of the platform
At IPO in 2017, "MagSense" referred to a superparamagnetic relaxometry (SPMR) system: a dedicated magnetic-sensor instrument paired with targeted nanoparticles. The prospectus-era business model envisaged an installed base of MagSense instruments generating high-margin recurring consumable revenue. The company later pivoted to using conventional clinical MRI scanners as the detection modality. This was a material strategic change: it removed the need to build and regulate a capital instrument and shifted regulatory classification towards an imaging agent (drug/biologic pathway, IND) rather than a device-plus-test (IDE pathway, for which an FDA Breakthrough Device designation had been obtained for the MagSense System and Test for staging HER2 breast cancer).
Business model and revenue model
| Revenue model element | Status | Evidence |
|---|---|---|
| Product sales (imaging agents) | Pre-commercial; no product approved | FY2025 Annual Report |
| Nanoparticle contract sales (research-use iron oxide nanoparticles) | Material in FY2023–FY2024 (A$1.27M receipts in FY2023; A$1.16M sale of goods in FY2024); nil in FY2025 after manufacturing footprint was closed | FY2023 Prelim; FY2025 Annual Report Note 5 |
| Licensing (PrecisionMRX®) | Licence to Biosensis (2024) for research-market manufacture and sale under Imagion's PrecisionMRX® trademark; milestones and royalties on net sales. No royalty revenue separately disclosed in FY2025. | Q3 FY2024 quarterly (28 October 2024) |
| Government incentives | Australian R&D Tax Incentive (A$3.53M received in 2023 for 2022; A$0.44M recognised FY2024; A$0.04M FY2025) and small grants | FY2023 Prelim; FY2025 Annual Report |
| Future model (management intent) | Commercialisation of MagSense® agents directly or via partnering/licensing with imaging/pharma companies; potential AI-enabled quantitative image interpretation tools | Stockhead/company releases 2025–2026 |
Revenue mix in FY2025: 0% product, 0% service, 0% subscription, 0% licensing; the A$73,031 of "revenue and other income" comprised interest income (A$32,369) and R&D tax incentive (A$40,662). In H1 2026, "revenue and other income" of A$525,934 was almost entirely a non-cash accounting gain on modification of convertible notes (A$524,897).
Value-chain position, customers and end-markets
Imagion sits at the discovery/clinical development stage of the diagnostic imaging agent value chain. Upstream it depends on contract manufacturers and antibody supply (manufacturers not named in reviewed filings); downstream it would sell to (or through) hospital radiology departments, breast imaging centres and imaging-agent distributors, ultimately reimbursed by payers. Its adjacency partners are MRI equipment vendors (Siemens Healthineers collaboration). Historical paying customers were research and industrial buyers of nanoparticles, including New Phase (Israel), which used particles for exploratory SaNP hyperthermia therapy.
End-markets targeted: (i) HER2-positive breast cancer staging and treatment-response imaging; (ii) prostate cancer detection/characterisation; (iii) ovarian cancer detection; (iv) exploratory brain (glioblastoma) and pancreatic cancer imaging via collaborations.
Independent characterisation
Imagion is best characterised as a single-asset, platform-optionality micro-cap biotech. Its scientific premise—targeted iron oxide nanoparticles as MRI molecular probes—is established in the academic literature, and its execution has advanced to a cleared US IND. The commercial question is whether a non-radioactive molecular MRI agent can achieve diagnostic accuracy and workflow economics competitive with sentinel node biopsy, ultrasound-guided biopsy, PET-based molecular imaging and surgical magnetic tracers. The financial reality is acute: the balance sheet showed net liabilities of A$3.42 million at 30 June 2026, cash of A$32,456 at that date (before approx. A$3.73 million of placement proceeds received July–August 2026), and convertible notes maturing in late 2026 with a conversion floor well above the prevailing share price.
Strategy
Stated strategic themes (FY2025 Annual Report and 2026 releases)
-
Return to mission: the world's first molecular MRI imaging technology. Re-establish and execute the MagSense® HER2 development plan through a US Phase 1b/2 trial.
-
Disciplined, low fixed-cost operating model. "Significantly reduced fixed costs of administration activities including its human resources"; G&A to be maintained at end-2025 levels "for the foreseeable future."
-
Pipeline breadth contingent on funds. Prostate and ovarian programs "will be resumed as funds become available."
-
Quantitative MRI and AI. Combine MagSense® agents with quantitative MRI sequences (Wayne State) so the agent's signature is uniquely detectable, laying the groundwork for automated/AI-assisted image analysis.
-
Leverage MRI-industry partnerships. Siemens Healthineers in-kind support for protocol optimisation and site technical support.
-
Non-dilutive funding. Pursuit of US federal grants (Case Western BPI application, May 2026) and the Australian R&D Tax Incentive.
Strategic initiatives in the last 24 months
| Date | Initiative | Type | Status |
|---|---|---|---|
| 2,024 | Restructuring: staff retrenchment, lease terminations, outsourcing of finance/company secretarial | Cost program | Completed |
| Oct 2024 | PrecisionMRX® out-licence to Biosensis | Monetisation of non-core asset | Active |
| Q1–Q4 2025 | GMP manufacture of new MagSense® HER2 clinical batch | Platform investment | Completed (release January 2026) |
| Q2 2025 | FDA briefing (pre-IND) | Regulatory | Positive feedback incorporated |
| Q2 2025 | Prostate clinical advisor appointed | Pipeline | Active |
| Aug–Dec 2025 | Wayne State MRI sequence optimisation | R&D partnership | Completed; positive |
| Dec 2025 | US President appointment | Leadership | Completed |
| Feb–Jun 2026 | IND submission and clearance | Regulatory | Cleared 2 June 2026 |
| May 2026 | Case Western federal grant application (prostate) | Non-dilutive funding | Pending |
| Jul 2026 | Siemens Healthineers collaboration renewal | Partnership | Active |
| Aug–Sep 2026 | CRO engagement, central IRB, site activation | Clinical execution | In progress |
Medium-term targets and guidance
Management provides no financial targets (revenue, margin or cash guidance). Operational guidance (HY2026 Report): initiate Part A as early as September 2026, report Part A results in Q1 2027 subject to recruitment, complete the trial within 18–24 months. Prior FY2025 Annual Report objectives for H1 2026—activating initial sites, opening enrolment and dosing the first cohort—were not achieved within H1 2026, reflecting the IND review cycle. ESG or sustainability commitments: none disclosed.
Products & Services
All products sit in the single R&D segment.
MagSense® HER2 Imaging Agent (MSH2IA) — lead clinical asset
| Attribute | Detail |
|---|---|
| Description | Iron oxide nanoparticle conjugated to a HER2-targeting antibody; intravenous MRI molecular imaging agent |
| Indication | Detection of nodal metastases (staging) in HER2-positive breast cancer; potential use in imaging response following neoadjuvant therapy |
| Clinical status | Phase 1 (Australia) completed 2023: met safety/tolerability endpoints; independent blinded radiologist panel found MRI contrast in nodes highly suspicious for tumour distinctly different from non-involved nodes. US IND 165081 cleared 2 June 2026 for a Phase 1b/2 study. Central IRB (Advarra) approval obtained c.September 2026. |
| Phase 1b/2 design | Multi-site, open-label, three parts: Part A safety and dosing; Part B optimised imaging protocol; Part C diagnostic performance. Expected duration 18–24 months. Seven US sites planned. Principal investigator: Dr Eghtedari, Section Chief of Women's Imaging, City of Hope (Los Angeles). CRO work orders signed August 2026. |
| Timing guidance | Part A initiation as early as September 2026; Part A results targeted Q1 2027, subject to recruitment (HY2026 Report). Prior guidance (Q1 2026 start, then Q2, then Q3 2026 recruitment) has slipped repeatedly. |
| Supply | New GMP batch manufactured Q1–Q4 2025; release testing completed January 2026; distribution to sites in progress August 2026. Contract manufacturer not named in reviewed filings. |
| Imaging protocol | Optimised quantitative MRI sequences developed with Wayne State University (2025), implemented with Siemens Healthineers technical support; expected to improve image quality and reduce imaging time at lower agent doses; positioned as a foundation for AI-assisted interpretation |
| Target customer | Breast imaging radiologists, surgical oncologists, cancer centres |
| Pricing model | — |
| Launch year | Not applicable (investigational) |
MagSense® Prostate Cancer Imaging Agent
| Attribute | Detail |
|---|---|
| Description | Targeted iron oxide nanoparticle formulation for prostate cancer detection on MRI; Monash University researchers also investigating the formulation in other cancers expressing the target antigen, such as triple-negative breast cancer |
| Status | Preclinical; described in FY2023 as ready for IND-enabling studies pending funding. No material expenditure in FY2025. |
| Supporting activities | Two A$50,000 Entrepreneurs' Programme grants (2021, 2023); WMIC 2022 data; clinical advisor Dr Leonardo Kayat-Bittencourt (Case Western Reserve University) appointed Q2 2025; May 2026 joint US federal Bioengineering Partnerships with Industry grant application with Case Western titled "Novel Iron-Based Nanoparticle for Advanced Detection and Characterization of Prostate Cancer on MRI" (outcome not yet disclosed) |
| Target customer | Urologists, uro-radiologists (multiparametric MRI users) |
| Pricing | — |
MagSense® Ovarian Cancer Imaging Agent
| Attribute | Detail |
|---|---|
| Status | Preclinical; two scientific posters at the American Association for Cancer Research annual meeting (2023); ready for IND-enabling studies pending funding (FY2023). No material expenditure in FY2025. |
| Target customer | Gynaecologic oncology and imaging |
Brain cancer program (collaboration)
Collaboration with Patrys Limited (initiated 2021), expanded via engagement with The University of Sydney to test MagSense® formulations in glioblastoma multiforme models. In-house research showed Patrys molecules can be combined with Imagion nanoparticles and remain biofunctional. Progress reports were expected in H1 2024; current status not publicly disclosed in reviewed filings.
Pancreatic cancer program (collaboration)
August 2023 MOU with Prestige Biopharma combining MagSense® molecular MRI with PBP1510 (PAUF-targeting antibody) for preclinical feasibility. Current status not publicly disclosed.
PrecisionMRX® superparamagnetic iron oxide nanoparticles
Research-use nanoparticles developed by Imagion for magnetic relaxometry and other biomedical applications where magnetic susceptibility is instrumental. Since October 2024, Biosensis holds a licence to manufacture and market under the PrecisionMRX® trademark to academic and industry researchers, paying Imagion milestone fees and royalties. No royalty income separately disclosed in FY2025.
Contract nanoparticle supply (discontinued)
Direct sales of nanoparticles manufactured in Imagion's former US facility, including to New Phase (Israel) for its SaNP hyperthermia program. Receipts rose from A$0.47 million (2022) to A$1.27 million (2023); A$1.16 million sale of goods in FY2024; nil in FY2025 following facility lease terminations.
Legacy MagSense® SPMR instrument system
Original platform comprising a magnetic relaxometry instrument and nanoparticles; FDA Breakthrough Device designation for the System and Test for HER2 staging. Superseded by the MRI-based approach; no active development disclosed.
Financial Narrative
Data notes
-
Source: FY2025 Annual Report (FY2025, FY2024 audited; five-year table for revenue and loss FY2021–FY2025); FY2023 Preliminary Final Report (FY2023 unaudited preliminary and FY2022 comparatives); FY2024 Statutory Financial Statements.
-
FY2023 audited revenue (A$4,970,756) and loss (A$12,473,916) per FY2025 Annual Report differ from the FY2023 preliminary figures (A$5,179,322 revenue; A$13,065,350 loss). The FY2025 Annual Report shows audited total equity at 1 January 2024 of -A$3,788,047 versus -A$4,685,456 in the preliminary report.
-
"Revenue" below means statutory "revenue and other income" including R&D tax incentive, as presented by the company in its five-year table.
-
EBITDA, net debt, free cash flow and ratios are analyst derivations from reported line items.
Income statement: notes and sources
Notes: FY2023 EBITDA derived from preliminary loss (-A$13,065.4K) plus finance costs and D&A; on audited loss the figure would be approx. -A$10,922.7K. Diluted EPS equals basic in all years (options anti-dilutive in a loss position). Gross profit, gross margin, operating margin and EBITDA margin are not meaningful: the company does not report cost of goods sold separately and revenue is dominated by tax incentives and non-operating gains. Simply Wall St's display of FY2025 "cost of revenue A$2.1M" is a misclassification of R&D expense. Revenue CAGR FY2021–FY2025 (analyst): approx. -60% per annum.
Half-year comparison: notes and sources
Source: HY2026 Report. H1 FY2026 revenue and other income consisted of interest (A$1,037) and a non-cash gain on modification of debt (A$524,897).
Balance sheet: notes and sources
Notes: FY2021 equity is the 1 January 2022 opening balance. FY2023 values are preliminary; audited 1 January 2024 equity was -A$3,788.0K. At 30 June 2026: total assets A$671.9K, cash A$32.5K, convertible notes and derivatives A$2,190.8K, trade payables A$1,900.4K, total liabilities A$4,091.2K, net liabilities A$3,419.3K (HY2026 Report). Unrecognised tax losses at 31 December 2025: A$17.7 million (Australia) and A$30.9 million (USA).
Cash flow
Quarterly cash balances (Appendix 4C): 30 September 2025 A$3.2 million; 31 December 2025 A$1.8 million; 31 March 2026 A$0.273 million (quarterly operating outflow A$1.279 million); 30 June 2026 A$32 thousand. Subsequent inflows: A$592,153 (1 July 2026, Tranche 1) and A$3,132,847 (18 August 2026, Tranche 2), both before costs.
Ratios
ROE is not meaningful for FY2023–FY2025 (negative equity). ROIC, net debt/EBITDA and interest coverage are not meaningful (negative EBITDA and operating income in all years). Cash conversion cycle is not meaningful (no recurring trading operations in FY2025). Note: the convertible notes carry no cash coupon; finance costs are predominantly non-cash amortisation of discount and transaction costs (A$843.5K of A$847.6K in FY2025).
Commentary on trends, inflections and drivers
FY2021–FY2023: build-out and cash consumption. The company exited FY2021 with A$13.4 million of cash and A$13.3 million of equity, following 2020 raises. FY2022 and FY2023 were investment years: employment expense rose to A$6.24 million in FY2023 as the company added clinical operations, manufacturing and quality staff for a planned US Phase 2; R&D expense rose to A$5.25 million in FY2023 for pharmacokinetic data collection and new agent manufacturing. Operating cash burn was approx. A$8.1–8.3 million per year. Revenue appeared to grow (A$4.97 million audited in FY2023) but was overwhelmingly the Australian R&D Tax Incentive (A$3.53 million) plus nanoparticle sales, not commercial imaging-agent revenue.
FY2023–FY2024 inflection: liquidity crisis and restructuring. By 31 December 2023, cash had fallen to A$227 thousand against current liabilities of A$5.68 million, and equity turned negative. The A$15 million Mercer facility proved largely undrawable because the A$0.50 floor price sat far above the share price. The company cut its workforce in three rounds, lost its CEO, paused all R&D and IND work, terminated US facility leases (removing A$3.2 million of right-of-use assets and approx. A$3.6 million of lease liabilities) and was suspended from trading for a period in 2024. FY2024's smaller loss (A$2.07 million) reflects both drastic cost cuts and a non-cash A$1.01 million gain on debt modification; underlying cash burn was A$1.27 million.
FY2025: restart under a lean model. R&D spending resumed (A$2.10 million) for GMP manufacturing, Wayne State protocol work and IND preparation, lifting the loss to A$4.31 million and operating burn to A$4.04 million. Employee costs fell to A$0.17 million as the company shifted to contractors and outsourced corporate services. Equity stayed negative (-A$2.16 million) despite A$3.5 million raised, because placement costs were high (A$1.13 million cost of issue including A$0.87 million value of lead-manager options) and losses absorbed the capital.
H1 2026: pre-trial spending, near-zero cash. R&D rose to A$1.59 million in the half as the IND process and trial start-up progressed. Cash fell to A$32 thousand at 30 June 2026 before placement proceeds arrived. A US$150,000 working-capital loan from the Executive Chairman (8% p.a., repayable within four months of each advance) on 28 July 2026 underscores how thin liquidity was between tranches.
Key forward driver: approx. A$0.006. Unless renegotiated again, this is a cash obligation comparable to most of the August 2026 raise.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products/services within |
|---|---|---|
Research & Development (sole segment) | All activities of the consolidated group: Imagion Biosystems Limited (Australian parent, listed) and Imagion Biosystems, Inc. (US operating subsidiary) | MagSense® HER2 Imaging Agent (clinical); MagSense® prostate and ovarian agents (preclinical); collaborative brain and pancreatic programs (exploratory); historical nanoparticle contract sales; PrecisionMRX® licence |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
R&D segment total revenue and other income incl. R&D tax incentive (AUD K) | 4,970.8 | 2,665.1 | 73.0 |
R&D segment sale of goods – nanoparticles (AUD K) | 1,266.2 | 1,160.2 | 0 |
R&D segment loss before tax (AUD K) | -12,473.9 | -2,067.0 | -4,309.5 |
Segment revenue YoY growth (%) | 61.9 | -46.4 | -97.3 |
Segment contribution to total revenue (%) | 100 | 100 | 100 |
Group Entities
| Entity | Jurisdiction | Ownership | Role |
|---|---|---|---|
Imagion Biosystems Limited | Australia | Listed parent | Holding company, ASX listing, capital raising, Australian R&D tax incentive claimant |
Imagion Biosystems, Inc. | United States | 100% | Operating subsidiary: R&D, regulatory (IND sponsor operations), clinical trial management; led by President Ward Detwiler |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue and other income incl. R&D tax incentive (AUD K) | 2,855.6 | 3,070.9 | 4,970.8 | 2,665.1 | 73.0 |
R&D tax incentive (AUD K) | — | 2,501.0 | 3,534.1 | 437.3 | 40.7 |
Sale of goods – nanoparticles (AUD K) | — | — | — | 1,160.2 | 0 |
Gain on modification of debt (AUD K) | — | 0 | 0 | 1,009.3 | 0 |
Research and development expense (AUD K) | — | 3,615.9 | 5,250.6 | 401.0 | 2,102.6 |
Employee benefits expense (AUD K) | — | 4,863.5 | 6,239.7 | 872.4 | 167.0 |
Professional fees (AUD K) | — | 1,037.8 | 1,888.2 | 864.3 | 949.3 |
General expenses (AUD K) | — | 1,424.0 | 1,693.2 | 871.2 | 263.1 |
Depreciation and amortisation (AUD K) | — | 1,108.2 | 1,183.2 | 392.1 | 8.8 |
Finance costs (AUD K) | — | 174.3 | 368.0 | 1,141.9 | 847.6 |
Share-based payments expense (AUD K) | — | 653.1 | 462.7 | 11.7 | 94.1 |
EBITDA – analyst derived (AUD K) | — | -8,524.7 | -11,514.1 | -533.0 | -3,453.1 |
Pre-tax income (AUD K) | -6,024.7 | -9,807.2 | -12,473.9 | -2,067.0 | -4,309.5 |
Net income (AUD K) | -6,024.7 | -9,807.2 | -12,473.9 | -2,067.0 | -4,309.5 |
Basic EPS as reported (A$ cents) | -0.230 | -0.348 | -40.920 | -4.599 | -1.553 |
Basic EPS adjusted for 40:1 consolidation – analyst (A$ cents) | -9.2 | -13.9 | -40.9 | -4.6 | -1.6 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Net margin (%) | -211.0 | -319.4 | -250.9 | -77.6 | -5,900.9 |
Income Statement and Per-Share Data (Half-Yearly)
| Metric | H1 FY2025 | H1 FY2026 |
|---|---|---|
Revenue and other income (AUD K) | 25.7 | 525.9 |
Research and development expense (AUD K) | 611.6 | 1,589.7 |
Professional fees (AUD K) | 317.9 | 455.6 |
Finance costs (AUD K) | 678.0 | 368.7 |
Net loss (AUD K) | -1,661.5 | -1,981.2 |
Basic EPS (A$ cents) | -0.83 | -0.40 |
Operating cash flow (AUD K) | -1,777.3 | -1,786.2 |
Cash at period end (AUD K) | 883.6 | 32.5 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (AUD K) | — | 9,975.6 | 4,586.3 | 2,803.7 | 2,044.2 |
Cash and equivalents (AUD K) | 13,393.8 | 4,446.1 | 227.1 | 2,670.5 | 1,847.7 |
Convertible notes incl. embedded derivatives (AUD K) | 0 | 0 | 3,550.0 | 2,793.5 | 2,656.1 |
Lease and hire purchase liabilities (AUD K) | — | 4,604.4 | 3,588.3 | 53.8 | 36.4 |
Total debt incl. leases – short term (AUD K) | — | 1,041.1 | 3,545.6 | 2,847.3 | 2,692.5 |
Total debt incl. leases – long term (AUD K) | — | 3,563.3 | 3,592.7 | 0 | 0 |
Net debt – analyst derived (AUD K) | — | 158.3 | 6,911.2 | 176.8 | 844.8 |
Total liabilities (AUD K) | — | 5,298.1 | 9,271.7 | 5,086.7 | 4,206.1 |
Total equity (AUD K) | 13,305.3 | 4,677.5 | -4,685.5 | -2,283.0 | -2,161.9 |
Goodwill and intangibles (AUD K) | — | 0 | 0 | 0 | 0 |
Working capital – analyst derived (AUD K) | — | 3,255.6 | -5,074.0 | -2,301.3 | -2,170.4 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | — | -8,074.2 | -8,316.0 | -1,270.6 | -4,043.7 |
Capital expenditure (AUD K) | — | -507.3 | -190.4 | 0 | 0 |
Free cash flow – analyst derived (AUD K) | — | -8,581.5 | -8,506.3 | -1,270.6 | -4,043.7 |
Proceeds from share issues (AUD K) | — | 0 | 2,382.8 | 3,125.2 | 3,500.3 |
Proceeds from convertible notes (AUD K) | — | 0 | 3,500.0 | 720.0 | 0 |
Net financing cash flow (AUD K) | — | -962.1 | 4,291.6 | 3,609.8 | 3,242.7 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Return on equity on closing equity (%) | -45.3 | -209.7 | — | — | — |
Return on assets on closing assets (%) | — | -98.3 | -272.0 | -73.7 | -210.8 |
Current ratio (x) | — | 2.88 | 0.11 | 0.55 | 0.48 |
Debt to equity incl. leases (x) | — | 0.98 | — | — | — |
Asset turnover (x) | — | 0.31 | 1.08 | 0.95 | 0.04 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
United States revenue and other income (AUD K) | 520.2 | 1,580.2 | 1,208.5 | 0 |
Australia revenue and other income (AUD K) | 49.8 | 65.0 | 1,019.4 | 32.4 |
Australia R&D tax incentive (AUD K) | 2,501.0 | 3,534.1 | 437.3 | 40.7 |
United States YoY growth (%) | — | 203.8 | -23.5 | -100.0 |
Australia (excl. R&D tax incentive) YoY growth (%) | — | 30.7 | 1,467.7 | -96.8 |
Share Price and Share Count (millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Share price at financial year end (AUD) | 3.040 | 0.960 | 0.355 | 0.023 | 0.025 |
Shares on issue at year end (millions) | — | 28.0 | 32.6 | 201.3 | 487.5 |
Share Price & Returns
| Period | Approximate total return | Basis |
|---|---|---|
1 year | approx. -80% | From approx. A$0.031 (21 October 2025 release price) |
3 years | approx. -98% | From A$0.355 consolidated-equivalent at 31 December 2023 (closest disclosed reference) |
5 years | approx. -99.8% | From A$3.040 consolidated-equivalent at 31 December 2021; YCharts reports a 5-year maximum drawdown of 99.93% (OTC line) |
Since IPO | approx. -99.9% | IPO A$0.20 pre-consolidation, equal to A$8.00 post-consolidation equivalent |
Valuation Multiples
| Multiple | Imagion | Comment |
|---|---|---|
Market capitalisation | approx. A$4.8M | approx. 801M shares at A$0.006 |
Enterprise value | approx. A$4–6M (estimate) | Adds approx. A$2.2M convertible notes (carrying value 30 June 2026) and US$150K chairman loan if drawn; deducts post-raise cash (not disclosed for 30 September 2026) |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | No operating revenue |
P/B | n/m | Negative book value (NTA -0.63 cents per share at 30 June 2026) |
Capital Markets
| Item | Status |
|---|---|
Dividend history | None paid, declared or recommended in any period |
Dividend policy | None; capital retained for R&D |
Buyback authorisation | None ("There is no current on-market share buy-back") |
Credit ratings (Moody's / S&P / Fitch) | None (unrated) |
Capital Instruments
| Instrument | Face value (AUD) | Maturity | Terms |
|---|---|---|---|
Mercer Tranche 2 (remaining) | 558,000 | 31 December 2026 | Convertible at higher of 90% of lowest 15-day VWAP or floor A$0.025 |
Mercer Tranche 3 | 1,100,000 | 31 December 2026 | As above |
Mercer Tranche 4 | approx. 242,000 | 30 November 2026 | As above |
Mercer Tranche 5 (net of 2024 conversions) | approx. 382,000 (analyst estimate) | 31 December 2026 | As above |
CMF Tranche 6 | 330,000 | approx. October 2027 (18 months from 23 April 2026) | Floor A$0.025; 10.6M options at A$0.0297 |
Total estimated face value | approx. 2,780,000 (analyst derivation) | — | Carrying value A$2,160,348 plus A$30,489 derivatives at 30 June 2026 |
Executive Chairman loan | Up to US$150,000 | Within four months of each advance | 8% p.a.; optional conversion subject to approvals |
Analyst Conclusions
Management guidance
-
Initiate Phase 1b/2 Part A as early as September 2026, pending ethics, site contracts and training (HY2026 Report). Ethics approval has since been secured; first site activation and first patient dosing had not been announced in sources reviewed.
-
Report Part A results in Q1 2027, subject to recruitment.
-
Complete the three-part trial in 18–24 months.
-
Keep G&A costs at end-2025 levels; prostate and ovarian spending limited by funds.
-
No revenue, margin or cash-flow guidance.
Consensus expectations
No sell-side consensus exists.
Bull case
-
Regulatory de-risking achieved. FDA IND clearance plus central IRB approval and released GMP supply mean the remaining path to Part A data is operational. A positive safety/dose readout in Q1 2027 on a company valued at approx. A$5 million could re-rate the shares sharply, as the 52.9% intraday move on IND clearance showed.
-
Strategic partner optionality. Siemens Healthineers' renewed in-kind collaboration signals industry interest. Non-radioactive molecular MRI fits MRI vendors' push into quantitative and AI imaging, and imaging majors have paid for adjacent magnetic-tracer technology (Hologic/Endomag).
-
Lean structure. With employee costs below A$0.2 million per year and outsourced trial operations, incremental capital goes mostly to clinical work; H1 2026 R&D of A$1.59 million shows spending now concentrated on the trial.
Bear case
-
Balance sheet cannot carry the trial. Net liabilities of A$3.42 million, approx. A$2.8 million of notes due November–December 2026 with conversion uneconomic at a A$0.025 floor, and an 18–24 month trial imply further heavy dilution or restructuring well before Phase 2 completion.
-
Execution record. Every major timeline since IPO has slipped: first-in-human from 2018 to 2021, Phase 2 start from Q1 2026 to late 2026. Phase 1 recruitment was slow. Delay compounds the funding gap.
-
Commercial uncertainty. Even with positive data, MagSense® must outperform established, reimbursed standards (sentinel node biopsy, ultrasound-guided biopsy) and compete with well-capitalised PET and surgical-tracer franchises. Approval would require Phase 3 scale funding the company does not have.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| By 31 Oct 2026 | Q3 FY2026 Appendix 4C: cash after placement, burn rate, site activation status |
| Q4 2026 | First site activation; first patient dosed in Part A |
| 30 Nov – 31 Dec 2026 | Convertible note maturities: repayment, extension, conversion or refinancing |
| Q4 2026 – Q1 2027 | Repayment or conversion of Executive Chairman loan |
| Q1 2027 | Part A results (safety, dosing) |
| Late Feb 2027 | FY2026 Annual Report (going-concern assessment) |
| 2026–2027 | Outcome of Case Western federal grant application |
| Ongoing | Any partnering, licensing or strategic transaction; further placements and option issuance; share price relative to A$0.025 note floor |
Analyst verdict
Imagion Biosystems has done the hard scientific and regulatory work that many micro-cap platform companies never complete. It generated first-in-human safety data, rebuilt GMP clinical supply after a near-collapse in 2024, secured a US IND for a multi-site Phase 1b/2 study, and retained a credible MRI-industry partner in Siemens Healthineers. The concept—targeted iron oxide nanoparticles that make MRI molecularly specific without radioactivity—addresses a real clinical question in HER2-positive breast cancer staging and, potentially, treatment-response monitoring.
The financial position, however, dominates the investment case. The group ended June 2026 with A$32 thousand in cash and A$3.42 million of net liabilities. Its two auditors' reports carry going-concern material-uncertainty language, and approx. A$2.8 million of secured, zero-coupon convertible notes mature in November–December 2026 at a conversion floor roughly four times the prevailing share price. The A$3.73 million raised in mid-2026 funds trial start-up, not trial completion. Share count has grown about 25-fold since January 2024, and more than 580 million options overhang the register. Governance is thin: an executive chairman without a CEO, and board members whose firms are significant paid service providers.
The equity is therefore a high-risk option on Part A clinical data and on management's ability to keep refinancing the note stack. A positive, on-time Part A readout in early 2027, combined with a partnership or non-dilutive funding, would validate the platform and could justify a materially higher valuation from a A$5 million base. Conversely, a further slip in site activation, a failed note renegotiation, or weak early imaging data would likely force deeply dilutive recapitalisation. Our assessment: scientifically credible, strategically focused, financially fragile. Suitable only as a speculative position sized for total loss, with the Q3 FY2026 cash report and the December 2026 note maturities as the decisive near-term tests.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education |
|---|---|---|---|---|
Robert (Bob) Proulx | Executive Chairman (executive director) | Director 6 December 2016; Chairman since 2017 IPO; CEO February 2015–June 2023; interim executive from 15 January 2024 | 30+ years in computing, life sciences and diagnostics: President and GM, Menarini-Silicon Biosystems; VP Marketing and Sales, Nanogen; SVP, Gene Logic; GM Life Sciences, IGEN International; VP Marketing, Packard BioScience; President and COO, Senior Scientific LLC; director of Semrock and Quantapore | M.A. and B.A., State University of New York at Albany; Executive MBA, Penn State Smeal College of Business |
Brett Mitchell | Non-Executive Director | 14 June 2024 | Corporate finance executive, 15+ years with ASX companies; Executive Chairman of Javelin Minerals (ASX: JAV), Non-Executive Chairman of Uvre (ASX: UVA); former director of Delta Lithium, MGC/Argent Biopharma, Mount Ridley Mines; founder of two financial advisory businesses | — |
Melanie Leydin | Non-Executive Director and Company Secretary | 2024 (approx. 1.5–1.7 years' tenure per Simply Wall St) | Chartered Accountant; principal of Leydin Freyer (2000–2021, acquired by Vistra); Executive Vice President Global Solutions, Southeast Asia at Vistra; director of Invion (ASX: IVX) and Unico Silver (ASX: USL) | Bachelor of Business (Accounting and Corporate Law), Swinburne University; FCA; FGIA |
Dr Nina Webster | Non-Executive Director | 1 September 2025 | Managing Director and CEO of Dimerix (ASX: DXB); former Commercial Director of Acrux; former Director of Commercialisation and IP at Immuron; Chair of SYNthesis BioVentures; NED of Linear Clinical Research | PhD Pharmaceutics; Bachelor of Pharmacology; Master of IP Law; Executive MBA |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Since | Background |
|---|---|---|---|
Ward Detwiler | President, Imagion Biosystems, Inc. (US subsidiary); reports to the Board; primary responsibility for growth and development of the consolidated company | President from 1 December 2025; Chief Business Officer from July 2024 | Founder and CEO of SpinTech MRI (MRI software), raised successive venture rounds |
Dr Leonardo Kayat-Bittencourt | Prostate cancer clinical advisor | Q2 2025 | Professor of Radiology and Urology, Case Western Reserve University; Vice Chair of Innovation, University Hospitals Cleveland |
Dr Eghtedari | Principal Investigator, Phase 1b/2 | April 2026 | Section Chief, Women's Imaging, City of Hope; independent reviewer in Phase 1 |
Directors' Remuneration
| Name | Salary and fees | Superannuation | Share-based payments | Total FY2025 | Total FY2024 |
|---|---|---|---|---|---|
Robert Proulx (Executive Chairman) | 127,150 | 0 | 50,916 | 178,066 | 62,862 |
Brett Mitchell (NED) | 52,000 | 0 | 32,344 | 84,344 | 30,506 |
Melanie Leydin (NED and Company Secretary) | 60,000 | 0 | 0 | 60,000 | 25,000 |
Dr Nina Webster (NED, from 1 September 2025) | 20,000 | 2,400 | 0 | 22,400 | 0 |
Total KMP | 259,150 | 2,400 | 83,260 | 344,810 | 271,618 |
Governance Overview
| Attribute | Assessment |
|---|---|
Board size | 4 |
Chair/CEO separation | No: Executive Chairman also performs the top executive role; no CEO |
Independence | Arguably 1 of 4 clearly independent (Webster). Leydin's firm and Mitchell's firm receive material fee income from the company, which under ASX Corporate Governance Principles would typically impair independence. Proulx is executive. |
Committees | No separate remuneration committee; the Board acts as remuneration committee given company size (FY2025 Annual Report). Audit committee arrangements not detailed in reviewed sections. |
Gender diversity | 2 of 4 directors female (50%) |
Meeting attendance FY2025 | 16 board meetings: Proulx 16/16; Mitchell 15/16; Leydin 16/16; Webster 3/3 |
Average board tenure | Approx. 1.5 years per Simply Wall St (new board following 2024 turnover) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Jun 2023 | Dr Isaac Bright appointed CEO; Proulx retires as CEO | Planned succession for US Phase 2 |
15 Jan 2024 | Bright resigns; Proulx interim | Liquidity crisis |
3 May 2024 | Naumoska and Angus resign | Board downsizing |
13 May 2024 | CFO and Company Secretary Hollis resigns | Cost reduction; outsourced to Vistra |
14 Jun 2024 | Mitchell appointed | Capital-markets capability |
22 Aug 2024 | Harsh, Ludvigson, Van Asten resign | Board refresh after recapitalisation |
1 Sep 2025 | Webster appointed | Biotech operating experience |
1 Dec 2025 | Detwiler appointed US President | Execution lead for IND and trial |
Major Shareholders
| Holder category | Holding | Source |
|---|---|---|
Robert Proulx | 4,470,749 shares (31 December 2025) plus 4,441,667 options and 600,000 performance rights | FY2025 Annual Report |
Brett Mitchell | 5,937,575 shares plus 6,166,667 options and 1,250,000 performance rights | FY2025 Annual Report |
Dr Nina Webster | 565,211 shares | FY2025 Annual Report |
Total director holdings | 10,973,535 shares = approx. 2.3% of 487.5 million shares at 31 December 2025 (lower after 2026 placements unless directors participated) | Analyst calculation |
Mercer Street / C/M Capital | Convertible noteholders and option holders; equity stake after conversions not disclosed | FY2025 Annual Report; HY2026 Report |
Manhattan Scientifics, Inc. | Projected approx. | Manhattan Scientifics release 2017 |
Competitive Landscape
Key Competitors
| Competitor | Segment / overlap | Relative positioning vs Imagion |
|---|---|---|
Surgical sentinel lymph node biopsy (standard of care, radioisotope and blue dye) | Nodal staging in breast cancer | Entrenched, reimbursed, accurate; invasive. MagSense® aims to reduce need for some procedures. |
Endomag (Magtrace® SPIO tracer and Sentimag® system; acquired by Hologic in 2024) | Magnetic nanoparticle tracer for sentinel node localisation | Commercial, iron-oxide-based, non-radioactive; surgical localisation rather than pre-operative molecular imaging. Most direct technology analogue. |
Hologic | Breast imaging (mammography, tomosynthesis, biopsy) and, via Endomag, magnetic localisation | Dominant breast health franchise; distribution power |
GE HealthCare (Pharmaceutical Diagnostics; Cerianna FES PET agent; gadolinium contrast) | Contrast and molecular imaging agents; MRI systems | Scale player in contrast media and PET agents |
Bayer (Gadovist and MRI contrast portfolio) | MRI contrast agents | Incumbent in MRI contrast; non-targeted agents |
Bracco Imaging | MRI and CT contrast agents | Incumbent; potential partner/acquirer profile |
Guerbet | MRI contrast agents | Incumbent mid-cap |
Lantheus Holdings | Radiopharmaceutical molecular imaging (PSMA PET) | Leader in PSMA PET for prostate; competes with future MagSense® prostate agent |
Telix Pharmaceuticals (ASX: TLX) | Radiopharmaceutical imaging (PSMA PET, kidney, glioma) | ASX-listed molecular imaging leader; competes for investor capital and prostate imaging market |
Clarity Pharmaceuticals (ASX: CU6) | Copper-64 theranostic imaging agents | Clinical-stage ASX radiopharma; well-funded relative to Imagion |
Lumicell (LumiSystem fluorescence imaging) | Intra-operative breast cancer margin imaging | Approved optical molecular imaging in breast surgery |
Academic HER2-PET agents (e.g., zirconium-89 trastuzumab) | HER2 molecular imaging | Research-stage, radioactive; validate HER2 imaging concept |
Peer Comparison FY2025
| Metric | Imagion (FY2025) | Lantheus (FY2024) | Telix (FY2024) | GE HealthCare (FY2024) |
|---|---|---|---|---|
Revenue | A$0.07M (other income only) | approx. US$1.5B | approx. A$0.78B | approx. US$19.7B |
Revenue growth | -97% | approx. +18% | approx. +56% | approx. flat |
Profitability | Net loss A$4.3M | Profitable | Profitable at operating level | Profitable |
R&D intensity | n/m (R&D far exceeds revenue) | Mid-single-digit to low-double-digit % | High-single to low-double-digit % | Mid-single-digit % |
Commercial stage | Phase 1b/2 | Commercial | Commercial | Commercial |
Recent Developments
--



